Euro Manganese reports significant permitting progress
Vancouver, British Columbia--(Newsfile Corp. - May 27, 2026) - Euro Manganese Inc. (TSXV: EMN) (ASX: EMN) (FSE: E06) is pleased to provide a progress update on the permitting process for the Chvaletice Manganese Project (the "Project") by its wholly-owned subsidiary MANGAN Chvaletice, s.r.o. (together with Euro Manganese Inc. the "Company" or "Euro Manganese"). Taken together, the permitting milestones achieved to date significantly de-risk the Project by advancing key regulatory approvals, improving development visibility and supporting a clearer pathway toward construction and future operations. HIGHLIGHTS Construction Permit for infrastructure relocation received in May 2026 Land Planning Permit for the processing plant received in April 2026 Construction Permit for the technological bridge received in March 2026 Land Planning Permit for the railway and shunting yard submitted, with a decision expected in summer 2026 Determination of the mining lease received in January 2025 Environmental and Social Impact Assessment ("ESIA") received in March 2024 Martina Blahova, President and CEO of Euro Manganese, commented: "Securing these permits marks a major milestone for the Chvaletice Manganese Project and underscores the meaningful progress we continue to make across the permitting landscape.
Each of these steps strengthens our position, reduces project risk, and enhances project maturity as we advance toward construction and long-term operations. We remain fully committed to working collaboratively with local and governmental authorities and stakeholders to ensure responsible, timely development that meets all regulatory and planning requirements. The permitting achievements to date significantly de-risk the Project by advancing key approvals and providing a clear, and confident pathway to execution.
Permitting progress, together with the recently released Preliminary Economic Assessment 1  creates a strong foundation as we move into 2027, when we expect to deliv